Skip to content
    ClavystBio logo

    ClavystBio

    SingaporeFounded 2022
    www.clavystbio.comLinkedIn
    Biotech & Life Sciences

    ClavystBio is a life sciences investor and venture builder established by Temasek in 2022 to accelerate the commercialization of biotech, medtech, and digital health breakthroughs from Singapore. It operates through three pillars—collaborate, venture, and build—investing in early-stage ventures while providing innovation infrastructure like Node 1.

    41% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 4 prior). Average disclosed round size is $59.6M (across 18 rounds with reported amounts).

    Find people at ClavystBio on Goldilocks AI

    Portfolio

    16

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    2

    Team

    Jamie WONG

    Jamie WONG

    Director, Finance

    Yingmin WANG, PhD

    Yingmin WANG, PhD

    Director, MedTech

    Yvonne KOH, PhD

    Yvonne KOH, PhD

    Director, Therapeutics

    Charles Yiliu ZHANG, PhD

    Charles Yiliu ZHANG, PhD

    Assistant Vice President, Therapeutics

    Cheryl TAN, MD

    Cheryl TAN, MD

    Assistant Vice President, MedTech

    Johnny NG, PhD

    Johnny NG, PhD

    Assistant Vice President, Therapeutics

    Vincent LAI

    Vincent LAI

    Vice President, Cybersecurity & IT

    Marcus TAN, PhD

    Marcus TAN, PhD

    Senior Associate

    Ning MAO, PhD

    Ning MAO, PhD

    Senior Associate

    Anselm TAN

    Anselm TAN

    MedTech Lead

    Carol CHAN

    Carol CHAN

    Executive Assistant and Office Manager

    Ewen POH

    Ewen POH

    Human Resources Manager

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    22 investments
    CompanyRoundAmountDate
    Zenflow logoZenflowSeries D$52MOct 2026
    Respiree Pte Ltd logoRespiree Pte LtdSeries A—Feb 2026
    BBiobot SurgicalUnknown—Jan 2026
    Cirrus Therapeutics logoCirrus TherapeuticsSeed$11MOct 2025
    Respiree Pte Ltd logoRespiree Pte LtdSeries A$11.6MJul 2025
    Allay Therapeutics logoAllay TherapeuticsSeries D$57.5MJun 2025
    Nuevocor logoNuevocorSeries B$45MMay 2025
    Callio Therapeutics logoCallio TherapeuticsSeries A$187MMar 2025
    Nuevocor logoNuevocorSeries B$45MJan 2025
    Allay logoAllaySeries D$57.5MJan 2025
    Respiree Pte Ltd logoRespiree Pte LtdSeries A$11.6MJan 2025
    NNSG BioLabsUnknown$14.5MJan 2024
    Automera logoAutomeraSeries A$16MSep 2023
    Paratus Sciences logoParatus SciencesSeries D—Feb 2023
    Paratus Sciences logoParatus SciencesSeries A$100MFeb 2023
    LLeyden LaboratoriesSeries B$40MJan 2022
    Leyden Labs logoLeyden LabsSeries B$140MJan 2022
    LLeyden LaboratoriesSeries A—Mar 2021
    SunBird Bio logoSunBird BioUnknown$14M—
    CCalliotxSeries A$187M—
    Sunbird logoSunbirdUnknown$14M—
    Leyden Labs logoLeyden LabsUnknown$70M—

    Top Co-Investors

    EDBI9 shared
    SEEDS Capital8 shared
    Polaris Partners8 shared
    F-Prime Capital5 shared
    Casdin Capital4 shared
    GV4 shared
    Bluebird Ventures4 shared
    European Innovation Council (EIC)4 shared
    The Invus Group, LLC4 shared
    We Venture Capital3 shared
    Adaptive Capital Partners3 shared
    XYZ Venture Capital2 shared
    Leaps by Bayer2 shared
    Alexandria Venture Investments2 shared
    ARCH Venture Partners2 shared
    Jeito Capital2 shared
    Omega Funds2 shared
    Frazier Healthcare Partners2 shared
    Pureos Bioventures2 shared
    Frazier Life Sciences2 shared

    Last updated: 20 October 2026